Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
January 09, 2023 08:00 ET
|
Cogent Biosciences, Inc.
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from...
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 11, 2022 17:30 ET
|
Cogent Biosciences, Inc.
- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up - Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients...
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
December 05, 2022 08:00 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
November 28, 2022 16:15 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 14, 2022 07:00 ET
|
Cogent Biosciences, Inc.
Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in...
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
November 09, 2022 08:00 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
November 03, 2022 09:05 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
October 26, 2022 07:00 ET
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 09, 2022 07:00 ET
|
Cogent Biosciences, Inc.
On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead-in data from Phase 3 PEAK trial planned for 1H23 Ended 2Q 2022...